Kaival Brands Innovations Group, Inc.

What they do

Kaival historically sold, marketed and distributed electronic nicotine delivery system (ENDS) products, principally the Bidi Stick, in the United States. Following a June 2024 patent infringement complaint filed by the RJ Reynolds Entities with the International Trade Commission, the company has not imported any Bidi Sticks and currently generates no revenue from Bidi Stick sales. Its current primary source of revenue is an international licensing agreement with Philip Morris Products S.A., a wholly owned affiliate of Philip Morris International. Subsidiary Kaival Labs has not launched any Kaival-branded products or white-label solutions and has acquired vaporization and inhalation intellectual property from GoFire, Inc.

Revenue drivers

• PMPSA international licensing agreement — Described in both the 10-K and 10-Q as the company's current primary source of revenue, an international licensing arrangement with Philip Morris Products S.A. This replaced the Bidi Stick as the main revenue source.
• Bidi Stick (discontinued) — Until October 2024 the Bidi Stick was the primary revenue source as remaining inventory was sold. The company has not imported Bidi Sticks since the ITC Complaint and reports no current Bidi Stick revenue.
• Kaival Labs / GoFire IP — Wholly owned subsidiary formed in August 2020 that has not commenced branded product sales or white-label services. It acquired vaporization and inhalation IP from GoFire in May 2023 with the aim of near-term third-party licensing in cannabis, hemp/CBD, nicotine and nutraceutical markets.

Recent performance

Annual revenue fell from $58.8M in 2021 to $13.1M in 2023, $6.9M in 2024 and $484,661 in 2025. Net losses were $16.6M in 2025, following $6.7M in 2024, $11.1M in 2023 and $14.4M in 2022. Operating cash flow was negative $2.8M in 2025. The most recent quarters reported revenue of $92,588 (October 2025), $92,938 (January 2026), $37,530 (April 2026) and $55,254 (July 2026). At July 31, 2026 total assets were $297,725, total liabilities were $542,132, shareholders' equity was negative $244,407 and cash and equivalents were $0.00.

Strategy

The company's stated focus is the international licensing agreement with PMPSA, which it identifies as its current primary revenue source. Through Kaival Labs it holds vaporization and inhalation IP acquired from GoFire and intends to pursue third-party licensing in cannabis, hemp/CBD, nicotine and nutraceutical markets, and to develop new products based on those assets. No Kaival-branded products have been launched and no white-label wholesale services have begun. The previously announced business combination with Delta Corp Holdings Limited was mutually terminated on September 11, 2025, with Delta releasing all related claims. The company has also received multiple delisting notices and reported director or officer changes and amended charter or bylaws documents since the last 10-K.

Risks

• ITC patent action and Bidi consent order — The RJ Reynolds Entities' Section 337 complaint sought exclusion and cease-and-desist orders on the Bidi Stick, and in December 2024 Bidi entered a consent order to cease all importation and distribution of the Bidi Stick until the asserted patent expires in October 2026.
• Revenue concentration in a single licensing counterparty — The company states its current primary source of revenue is the international licensing agreement with PMPSA, so its results depend on that single relationship.
• Negative equity and no cash on hand — At July 31, 2026 shareholders' equity was negative $244,407, total liabilities of $542,132 exceeded total assets of $297,725, and cash and equivalents were $0.00.
• Listing-rule failures — The company reported delisting notices or listing-rule failures on 2025-04-04, 2025-10-03 and 2025-11-17.

Outlook

Management points to the PMPSA international licensing agreement as the current primary revenue source, replacing the Bidi Stick business that ceased after the ITC Complaint. Kaival Labs is expected to pursue third-party licensing of the GoFire vaporization and inhalation IP, though no Kaival-branded products or white-label services have commenced. The Delta business combination was terminated in September 2025, removing that transaction from the stated path forward. The Bidi consent order and any ITC exclusion order extend until the asserted patent expires in October 2026.